The use of selective estrogen receptor modulators on bone health in men

References

• Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733.
   PubMed Web of Science ®Google Scholar
• Liu GM, Xu CJ, Kong N, et al. Age-related differences in microstructure, density and biomechanics of vertebral cancellous bone of Chinese males. Aging Male. 2012;15:233–239.
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513–521.
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen TV, Eisman JA, et al. The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab. 2014;99:415–423.
   PubMed Web of Science ®Google Scholar
• Bliuc D, Tran T, Alarkawi D, et al. Secular changes in postfracture outcomes over 2 decades in Australia: a time-trend comparison of excess postfracture mortality in two birth controls over two decades. J Clin Endocrinol Metab. 2016;101:2475–2483.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
   PubMed Web of Science ®Google Scholar
• Tenover JS. Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Baillieres Clin Endocrinol Metab. 1998;12:419–425.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. Aging Male. 2012;15:187–197.
   PubMed Web of Science ®Google Scholar
• Khera M, Broderick GA, Carson CC III, et al. Adult-onset hypogonadism. Mayo Clin Proc. 2016;91:908–926.
   PubMed Web of Science ®Google Scholar
• Mohamad NV, Soelaiman IN, Chin KY. A review on the effects of Androgen Deprivation Therapy (ADT) on bone health status in men with prostate cancer. Endocr Metab Immune Disord Drug Targets. 2017;17:276–284.
   PubMed Web of Science ®Google Scholar
• Miller LE, Pierson LM, Pierson ME, et al. Age influences anthropometric and fitness-related predictors of bone mineral in men. Aging Male. 2009;12:47–53.
   PubMed Web of Science ®Google Scholar
• Nelson DM, Peterson AC. Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer. Aging Male. 2010;13:120–123.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Ewing SK, Taylor BC, et al. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density—the osteoporotic fractures in men study. J Clin Endocrinol Metab. 2010;95:4314–4323.
   PubMed Web of Science ®Google Scholar
• Vandenput L, Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol. 2009;5:437–443.
   PubMed Web of Science ®Google Scholar
• Movérare S, Venken K, Eriksson A-L, et al. Differential effects on bone of estrogen receptor α and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci USA. 2003;100:13573–13578.
   PubMed Web of Science ®Google Scholar
• Ho-Pham LT, Nguyen ND, Nguyen TV. Quantification of the relative contribution of estrogen to bone mineral density in men and women. BMC Musculoskelet Disord. 2013;14:366.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, von Schoultz B, Nguyen TV, et al. Sex hormone levels as determinants of bone mineral density and osteoporosis in Vietnamese women and men. J Bone Miner Metab. 2015;33:658–665.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618–629.
   PubMed Web of Science ®Google Scholar
• Ohta H. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties]. Clin Calcium. 2004;14:73–80.
   PubMedGoogle Scholar
• Frasor J, Stossi F, Danes JM, et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004;64:1522–1533.
   PubMed Web of Science ®Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618.
   PubMed Web of Science ®Google Scholar
• Kastelan D, Giljevic Z, Kraljevic I, et al. Selective estrogen receptor modulators: a possible new treatment of osteoporosis in males. Med Hypotheses. 2006;67:1052–1053.
   PubMed Web of Science ®Google Scholar
• Smith MR. Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis. Rev Urol. 2005;7:S30–S35.
   PubMedGoogle Scholar
• Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841–3846.
   PubMed Web of Science ®Google Scholar
• Fitts JM, Klein RM, Powers CA. Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis. J Androl. 2004;25:523–534.
   PubMedGoogle Scholar
• Fitts JM, Klein RM, Powers CA. Estrogen and tamoxifen interplay with T(3) in male rats: pharmacologically distinct classes of estrogen responses affecting growth, bone, and lipid metabolism, and their relation to serum GH and IGF-I. Endocrinology. 2001;142:4223–4235.
   PubMed Web of Science ®Google Scholar
• Broulik PD. Tamoxifen prevents bone loss in castrated male mice. Horm Metab Res. 2000;32:181–184.
   PubMed Web of Science ®Google Scholar
• Karimian E, Chagin AS, Gjerde J, et al. Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. J Bone Miner Res. 2008;23:1267–1277.
   PubMed Web of Science ®Google Scholar
• Broulik PD, Broulikova K. Raloxifen prevents bone loss in castrated male mice. Physiol Res. 2007;56:443–447.
   PubMed Web of Science ®Google Scholar
• Onoe Y, Miyaura C, Ito M, et al. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res. 2000;15:541–549.
   PubMed Web of Science ®Google Scholar
• Folwarczna J, Sliwinski L, Cegiela U, et al. Raloxifene similarly affects the skeletal system of male and ovariectomized female rats. Pharmacol Rep. 2007;59:349–358.
   PubMed Web of Science ®Google Scholar
• Khedr NF, El-Ashmawy NE, El-Bahrawy HA, et al. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. Fundam Clin Pharmacol. 2013;27:526–534.
   PubMed Web of Science ®Google Scholar
• Sturmer EK, Seidlova-Wuttke D, Sehmisch S, et al. Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res. 2006;21:89–96.
   PubMed Web of Science ®Google Scholar
• Stuermer EK, Sehmisch S, Tezval M, et al. Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats. World J Urol. 2009;27:547–555.
   PubMed Web of Science ®Google Scholar
• Kulak CA, Borba VZ, Kulak Junior J, et al. Bone disease after transplantation: osteoporosis and fractures risk. Arq Bras Endocrinol Metab. 2014;58:484–492.
   PubMedGoogle Scholar
• Folwarczna J, Kaczmarczyk-Sedlak I, Pytlik M, et al. Effect of low-dose tacrolimus coadministered with raloxifene on the skeletal system in male rats. Acta Pol Pharm. 2009;66:207–212.
   PubMed Web of Science ®Google Scholar
• Ke HZ, Qi H, Crawford DT, et al. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology. 2000;141:1338–1344.
   PubMed Web of Science ®Google Scholar
• Sato Y, Tando T, Morita M, et al. Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis. Biochem Biophys Res Commun. 2017;482:1430–1436.
   PubMed Web of Science ®Google Scholar
• Borjesson AE, Farman HH, Engdahl C, et al. The role of activation functions 1 and 2 of estrogen receptor-alpha for the effects of estradiol and selective estrogen receptor modulators in male mice. J Bone Miner Res. 2013;28:1117–1126.
   PubMed Web of Science ®Google Scholar
• Starnes LM, Downey CM, Boyd SK, et al. Increased bone mass in male and female mice following tamoxifen administration. Genesis. 2007;45:229–235.
   PubMed Web of Science ®Google Scholar
• Filipovic B, Sosic-Jurjevic B, Ajdzanovic V, et al. Tamoxifen stimulates calcitonin-producing thyroid C-cells and prevents trabecular bone loss in a rat model of androgen deficiency. J Anat. 2015;226:489–496.
   PubMed Web of Science ®Google Scholar
• Jardi F, Laurent MR, Dubois V, et al. A shortened tamoxifen induction scheme to induce CreER recombinase without side effects on the male mouse skeleton. Mol Cell Endocrinol. 2017;452:57–63.
   PubMed Web of Science ®Google Scholar
• Zhong ZA, Sun W, Chen H, et al. Optimizing tamoxifen-inducible Cre/loxp system to reduce tamoxifen effect on bone turnover in long bones of young mice. Bone. 2015;81:614–619.
   PubMed Web of Science ®Google Scholar
• Kaczmarczyk-Sedlak I, Folwarczna J, Cegiela U, et al. Raloxifene does not affect the changes in bone histomorphometric parameters induced by low dose tacrolimus in male rats. Acta Pol Pharm. 2006;63:301–306.
   PubMed Web of Science ®Google Scholar
• Meixner CN, Aref MW, Gupta A, et al. Raloxifene improves bone mechanical properties in mice previously treated with zoledronate. Calcif Tissue Int. 2017;101:75–81.
   PubMed Web of Science ®Google Scholar
• Ke HZ, Qi H, Chidsey-Frink KL, et al. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res. 2001;16:765–773.
   PubMed Web of Science ®Google Scholar
• Nowinska B, Cegiela U, Folwarczna J, et al. Effects of raloxifene on development of the methotrexate-induced changes in bone mechanical properties of male rats. Pharmacol Rep. 2007;59:359–364.
   PubMed Web of Science ®Google Scholar
• Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152–155.
   PubMed Web of Science ®Google Scholar
• Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316–1321.
   PubMed Web of Science ®Google Scholar
• Smith MR, Malkowicz SB, Brawer MK, et al. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011;186:2239–2244.
   PubMed Web of Science ®Google Scholar
• Doran PM, Riggs BL, Atkinson EJ, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001;16:2118–2125.
   PubMed Web of Science ®Google Scholar
• Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol. 2004;150:539–546.
   PubMed Web of Science ®Google Scholar
• Uebelhart B, Herrmann F, Pavo I, et al. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res. 2004;19:1518–1524.
   PubMed Web of Science ®Google Scholar
• Yu EY, Getzenberg RH, Coss CC, et al. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015;67:334–341.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Schwartz F, Rejnmark L, et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011;22:993–1001.
   PubMed Web of Science ®Google Scholar
• Alibhai SMH, Zukotynski K, Walker-Dilks C, et al. Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2017;167:341–350.
   PubMed Web of Science ®Google Scholar
• Cauley JA. Estrogen and bone health in men and women. Steroids. 2015;99:11–15.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 1996;276:1404–1408.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E. Hormone replacement and cancer. Br Med Bull. 1992;48:345–355.
   PubMed Web of Science ®Google Scholar
• Compston JE. HRT and osteoporosis. Br Med Bull. 1992;48:309–344.
   PubMed Web of Science ®Google Scholar
• Komesaroff PA, Fullerton M, Esler MD, et al. Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension. 2001;38:1011–1016.
   PubMed Web of Science ®Google Scholar
• Komesaroff PA, Fullerton M, Esler MD, et al. Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer. Clin Endocrinol (Oxf). 2002;56:745–753.
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–645.
   PubMed Web of Science ®Google Scholar
• Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs. 2004;5:1086–1093.
   PubMedGoogle Scholar
• Batra GS, Hainey L, Freemont AJ, et al. Evidence for cell-specific changes with age in expression of oestrogen receptor (ER) alpha and beta in bone fractures from men and women. J Pathol. 2003;200:65–73.
   PubMed Web of Science ®Google Scholar
• Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988;241:81–84.
   PubMed Web of Science ®Google Scholar
• Vidal O, Kindblom LG, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res. 1999;14:923–929.
   PubMed Web of Science ®Google Scholar
• Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988;241:84–86.
   PubMed Web of Science ®Google Scholar
• Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001;29:2905–2919.
   PubMed Web of Science ®Google Scholar
• Arnett TR, Lindsay R, Kilb JM, et al. Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen. J Endocrinol. 1996;149:503–508.
   PubMed Web of Science ®Google Scholar
• Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem. 1999;73:500–507.
   PubMed Web of Science ®Google Scholar
• Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002;30:368–376.
   PubMed Web of Science ®Google Scholar
• Viereck V, Grundker C, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003;88:4206–4213.
   PubMed Web of Science ®Google Scholar
• Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996;2:1132–1136.
   PubMed Web of Science ®Google Scholar
• Lin TC, Yang CY, Kao Yang YH, et al. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int. 2014;25:1503–1511.
   PubMed Web of Science ®Google Scholar
• Kunath F, Keck B, Antes G, et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med. 2012;10:96.
   PubMed Web of Science ®Google Scholar
• Eggemann H, Altmann U, Costa S-D, et al. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J Cancer Res Clin Oncol. 2018;144:337–341.
   PubMed Web of Science ®Google Scholar
• Wibowo E, Pollock P, Hollis N, et al. Tamoxifen in men: a review of adverse events. Andrology. 2016;4:776–788.
   PubMed Web of Science ®Google Scholar